RBC Capital raised the firm’s price target on AdaptHealth (AHCO) to $14 from $11 and keeps an Outperform rating on the shares after its Q4 earnings beat. The company saw a strong finish to 2024 and gave solid initial guidance, the analyst tells investors in a research note. Early signs that the strategic overhaul to the Diabetes business announced last quarter may be taking hold, the firm adds.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHCO: